Investigational New Drug Clearance Given to R-Ketamine

Article

The FDA has given Investigational New Drug clearance for a clinical drug-drug interaction study of R-ketamine (PCN-101).

Mykyta/AdobeStock

Mykyta/AdobeStock

The US Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to Atai Life Sciences to conduct a clinical drug-drug interaction study of R-ketamine (PCN-101). Atai intends to initiate the study early this year through its platform company, Perception Neuroscience, as part of the clinical development program for R-ketamine.1

PCN-101 is a single isomer of ketamine and pharmacologically a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. It belongs to a new class of glutamate receptor modulators with the potential for rapid acting antidepressant activity and antisuicidal effects.

In nonclinical depression model studies in rodents, research suggests that R-ketamine could possess longer durability and a potentially more favorable safety and tolerability profile than S-ketamine. An open-label clinical study also demonstrated rapid, durable response and limited dissociative adverse effects in treatment-resistant depression (TRD) patients after a single intravenous dose.

“TRD represents a large percentage of people with severe, difficult to treat depression who have failed to sufficiently respond to at least 2 different antidepressant treatments,” said Terence Kelly, PhD, CEO of Perception Neuroscience. “We believe that PCN-101 has the potential to offer a differentiated therapeutic effect, in terms of both efficacy and ease of administration, for clinicians and patients, as a potentially rapid-acting antidepressant. We look forward to progressing its clinical development.”

This clinical DDI trial will advance alongside an existing phase 2a proof-of-concept trial in TRD, which was recently initiated in Europe.2 Furthermore, Atai will run a bioavailability study in 2022, designed to bridge the IV formulation to a subcutaneous formulation of PCN-101, supporting the potential for at-home self-administration.

“We see great promise in PCN-101 as a potentially rapid-acting anti-depressant with a more favorable safety and tolerability profile than S-ketamine, which could enable at-home use,” said Florian Brand, CEO and Co-Founder of Atai Life Sciences. “With today’s IND clearance, we are excited to continue assessing the therapeutic potential of PCN-101 in the US, where, like elsewhere in the world, many patients struggle with treatment-resistant depression and desperately need innovative therapeutic options.”

References

1. Atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine program. News release. January 12, 2022. https://www.atai.life/2022/01/12/atai-life-sciences-announces-fda-investigational-new-drug-ind-clearance-for-pcn-101-r-ketamine-program

2. Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression. News release. September 14, 2021. Accessed January 12, 2022. https://ir.atai.life/news-releases/news-release-details/perception-neuroscience-initiates-phase-2a-study-pcn-101-r

Related Videos
Experts on MDD.
Experts on MDD.
depression
exciting, brain
treatment resistant depression
treatment resistant depression
Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?
© 2024 MJH Life Sciences

All rights reserved.